Company profile: Amyris
1.1 - Company Overview
Company description
- Provider of biotech chemical products made via advanced sugarcane-derived fermentation. Portfolio includes Neossance Squalane for cosmetics and skincare moisturization and barrier repair; Artemisinic Acid used in antimalarial treatments; Biosilica from sugarcane ashes for cosmetics; Neossance Hemisqualane as a plant-based silicone alternative; Biofene renewable specialty chemical building block; RealSweet Reb M zero-calorie sweetener.
Products and services
- Neossance Hemisqualane: A personal-care-grade plant-based alternative to silicone for use in personal care products, enabling silicone replacement in these formulations
- Neossance Squalane: A cosmetic-grade sustainable emollient used in cosmetics and skincare for moisturization and barrier repair in beauty formulations
- RealSweet Reb M: A food-grade zero-calorie sweetener, bioidentical to the rare steviol glycoside Reb M and derived from fermentation, for sweetening applications without sugar
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amyris
Aura Biosciences
HQ: United States
Website
- Description: Provider of virus-like drug conjugates (VDCs) using virus-like particles to target solid tumors by delivering cytotoxic drugs or nucleic acids. Develops Belzupacap Sarotalocan (Bel-sar) for first-line treatment of early-stage choroidal melanoma and other ocular oncology indications, with potential in choroidal metastasis, aiming to preserve vision and prevent metastatic disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aura Biosciences company profile →
Airna
HQ: United States
Website
- Description: Provider of RNA editing technologies and therapeutics, including the RESTORE+ RNA editing platform to optimize sequence, chemistry, and delivery for precise RNA editing to treat rare and common diseases. Offers RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD) and a pipeline addressing diseases with high unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Airna company profile →
BridgeBio Pharma
HQ: United States
Website
- Description: Provider of precision medicines for genetic diseases and cancers, developing assets including BBP-398 (SHP2 inhibitor for MAPK/RAS-driven cancers), BBP-631 (AAV5 gene therapy for congenital adrenal hyperplasia), BBP-818 (AAV gene therapy for classic galactosemia), BBP-589 (recombinant collagen 7 for dystrophic epidermolysis bullosa), BBP-681 (topical PI3KA inhibitor), and BBP-711 (GO inhibitor).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BridgeBio Pharma company profile →
Yourgene Health
HQ: United Kingdom
Website
- Description: Provider of molecular diagnostics employing next generation DNA analysis technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Yourgene Health company profile →
Biocytogen
HQ: China
Website
- Description: Provider of integrated solutions for antibody drug development, offering RenMab Mouse for fully human antibody discovery, RenLite for bispecific and multispecific antibody discovery, RenNano for heavy-chain-only antibodies, CRISPR/Cas9 gene editing to create humanized animal models, BioMice genetically modified models, and a bispecific ADC discovery platform targeting multiple tumor proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocytogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amyris
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amyris
2.2 - Growth funds investing in similar companies to Amyris
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amyris
4.2 - Public trading comparable groups for Amyris
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →